Vetoquinol is moving forward with the acquisition of Profender and Drontal spot-on and tablet wormers for cats and dogs.
The European Commission has approved, under the EU merger Regulation, the proposed acquisition of Bayer’s Animal Health Division by Elanco Animal Health. This decision is conditional on the divestment of several products, including the Profender and Drontal product families, as well as related ‘pipeline assets’, to be acquired by Vetoquinol.
The transaction is expected to close early August and remains subject to additional regulatory approvals and customary closing conditions.
Matthieu Frechin, CEO of Vetoquinol, said: “We are extremely pleased to share this major regulatory step towards the completion of the acquisition of the Profender and Drontal product lines.
“The acquisition of these two strong brands as well as the related pipeline is at the core of Vetoquinol strategy. On the one hand, they will significantly increase the size of our business and our visibility in the parasiticide segment, one of our strategic therapeutic areas. On the other hand, they will strengthen our portfolio of Essentials, the engine of our growth.”